Johnson & Johnson (NYSE:JNJ) Shares Purchased by Janney Montgomery Scott LLC

Posted by Defense World Staff on Jul 27th, 2023

Janney Montgomery Scott LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,322,622 shares of the company’s stock after buying an additional 73,292 shares during the quarter. Johnson & Johnson comprises about 0.8% of Janney Montgomery Scott LLC’s portfolio, making the stock its 14th biggest holding. Janney Montgomery Scott LLC owned about 0.05% of Johnson & Johnson worth $205,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its stake in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock worth $8,456,643,000 after purchasing an additional 294,671 shares during the period. Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. Finally, Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter valued at $4,609,399,000. Institutional investors and hedge funds own 67.57% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

JNJ stock opened at $172.72 on Thursday. The company has a market cap of $448.85 billion, a P/E ratio of 34.96, a PEG ratio of 2.87 and a beta of 0.55. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The business has a fifty day moving average of $160.60 and a 200-day moving average of $161.20.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the firm earned $2.59 earnings per share. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.76 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Raymond James raised their target price on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a report on Monday. Citigroup initiated coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Barclays lifted their price objective on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Atlantic Securities reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $171.60.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.